228 related articles for article (PubMed ID: 16724286)
21. [Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Sato S
Clin Calcium; 2007 Apr; 17(4):600-5. PubMed ID: 17404491
[TBL] [Abstract][Full Text] [Related]
22. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
[TBL] [Abstract][Full Text] [Related]
23. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
24. Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
Ström O; Landfeldt E; Garellick G
Osteoporos Int; 2015 Jan; 26(1):315-25. PubMed ID: 25297890
[TBL] [Abstract][Full Text] [Related]
25. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
26. [Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis].
Suzuki Y
Clin Calcium; 2006 Nov; 16(11):1834-42. PubMed ID: 17079850
[TBL] [Abstract][Full Text] [Related]
27. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
Iba K; Takada J; Hatakeyama N; Ozasa Y; Wada T; Yamashita T
J Orthop Sci; 2008 Sep; 13(5):438-41. PubMed ID: 18843458
[TBL] [Abstract][Full Text] [Related]
28. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
Gold DT; Trinh H; Safi W
Curr Med Res Opin; 2009 Aug; 25(8):1831-9. PubMed ID: 19530982
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Bilezikian JP
Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Lang A; Robbins S; Ström O
Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
[TBL] [Abstract][Full Text] [Related]
31. Persistence with weekly alendronate therapy among postmenopausal women.
Lo JC; Pressman AR; Omar MA; Ettinger B
Osteoporos Int; 2006; 17(6):922-8. PubMed ID: 16609824
[TBL] [Abstract][Full Text] [Related]
32. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Thomson AB; Marshall JK; Hunt RH; Provenza JM; Lanza FL; Royer MG; Li Z; Blank MA;
J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
[TBL] [Abstract][Full Text] [Related]
33. Low incidence of anti-osteoporosis treatment after hip fracture.
Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
[TBL] [Abstract][Full Text] [Related]
34. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Angthong C; Angthong W
J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S214-20. PubMed ID: 22619933
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.
Amiche MA; Lévesque LE; Gomes T; Adachi JD; Cadarette SM
J Bone Miner Res; 2018 Mar; 33(3):419-429. PubMed ID: 29068496
[TBL] [Abstract][Full Text] [Related]
36. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Gold DT; Safi W; Trinh H
Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
[TBL] [Abstract][Full Text] [Related]
37. Persistence with osteoporosis medication among newly-treated osteoporotic patients.
van Boven JF; de Boer PT; Postma MJ; Vegter S
J Bone Miner Metab; 2013 Sep; 31(5):562-70. PubMed ID: 23575910
[TBL] [Abstract][Full Text] [Related]
38. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
Watts NB; Worley K; Solis A; Doyle J; Sheer R
J Manag Care Pharm; 2004; 10(2):142-51. PubMed ID: 15032563
[TBL] [Abstract][Full Text] [Related]
39. Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Iolascon G; Gimigliano F; Orlando V; Capaldo A; Di Somma C; Menditto E
Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S137-41. PubMed ID: 24046038
[TBL] [Abstract][Full Text] [Related]
40. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
Rietbrock S; Olson M; van Staa TP
QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
